Cingulate (CING) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Mar, 2026Executive summary
Supplement corrects the beneficial ownership table to include a previously omitted 5% stockholder as of February 13, 2026.
The supplement amends the original proxy statement but does not update any other disclosures or reflect subsequent events.
Voting matters and shareholder proposals
Proxy voting instructions already submitted remain valid unless stockholders wish to change their vote.
Information on how to change or revoke votes is available in the proxy statement.
Board of directors and corporate governance
The table lists all directors and executive officers, including their beneficial ownership and voting power.
Addresses and voting/investment power details are provided for each listed stockholder.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cingulate
- Shareholders will vote on director election, auditor ratification, and expanding the equity incentive plan.CING
Proxy filing29 May 2026 - Key votes include director election, auditor ratification, and expanding the equity plan.CING
Proxy filing29 May 2026 - Board recommends approval of director election, auditor ratification, and equity plan amendment.CING
Proxy filing19 May 2026 - Q1 2026 net loss rose to $9.3M as cash climbed to $25.9M ahead of FDA review.CING
Q1 202614 May 2026 - CTX-1301 aims to disrupt the ADHD market with once-daily efficacy and strong clinical results.CING
Corporate presentation14 Apr 2026 - Advancing once-daily ADHD and anxiety drugs with $12M raised, but faces going concern risk.CING
Registration filing14 Apr 2026 - Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026